Lux Biosciences’ Voclosporin Phase II/III Results Presented at AAO

Results of Phase II/III studies of the experimental drug LX211(LUVENIQ; oral voclosporin)showed that this agent may have the ability to control the inflammation in uveitis and significantly reduce its rate of recurrence while lowering the amount of corticosteroids required for treatment. These results were presented at the American Association of Ophthalmology meeting and at a presentation at a satellite meeting of the American Uveitis Society (AUS).

The LX211-02 study was a double-masked, placebo-controlled, dose-ranging study that included 232 patients at 57 centers in North America, Europe and India. These patients had clinically inactive uveitis. Results of this trial showed that LX211 was able to reduce recurrence of inflammation by 50% over placebo at the 0.4 mg/kg twice daily dose (p<0.05)

Results of the LX211-01 study, which investigated LX211 in 218 patients with active, sight-threatening uveitis affecting the posterior segment of the eye. In this study, also a double-masked, placebo-controlled, dose-ranging trial, results showed the LX211 to be statistically significantly superior to placebo at weeks 16 and 24 in amount of vitreous haze.

Treatment with LX211 was well tolerated with moderate and manageable adverse effects.